A dose-finding study with remoxipride in the acute treatment of schizophrenic patients. Journal Articles uri icon

  • Overview
  • Research
  • Additional Document Info
  • View All


  • Two hundred and forty-two patients with acute schizophrenia were enrolled in a double-blind, comparative, dose-finding study of a novel antipsychotic, remoxipride. Remoxipride was evaluated in a low (30 to 90 mg), medium (120 to 240 mg) and a high (300 to 600 mg) dose range and compared with a haloperidol (15 to 45 mg), which was administered to a similar group of patients. The results support the antipsychotic effect of remoxipride, with maximum efficacy occurring at daily doses between 120 mg and 600 mg. Side-effects were more frequent at doses of remoxipride over 300 mg. In all groups, remoxipride caused consistently fewer extrapyramidal side-effects than haloperidol. The antipsychotic effect of remoxipride may be derived from specific blockade of dopamine D2 receptors in the mesolimbic tract. The findings also suggest that remoxipride may have a therapeutic effect on negative symptoms of schizophrenia.


  • Lapierre, YD
  • Ancill, R
  • Awad, G
  • Bakish, D
  • Beaudry, P
  • Bloom, D
  • Chandrasena, R
  • Das, M
  • Durand, C
  • Elliott, Digby

publication date

  • October 1992